Fig. 8

mt-e-CAFs delay fl-CC and mt-CC response to chemotherapy in an HSPG2-dependent manner for mt-CCs. a Schematic of timeline of subcutaneous injection of cancer cells with CAFs, tumor development, titanium window implantation, drug treatment, and longitudinal imaging. b Representative mCerulean lifetime maps (top images) and longitudinal quantification of mCerulean lifetimes (lower left hand panels) and of CDK1 activity (lower right hand panels) in fl-CCs injected with (i) fl-e-CAFs, with (ii) mt-e-CAFs WT or with (iii) mt-e-CAFs KO HSPG2 (mixed population) 24 h, 48 h, and 72 h after treatment with control or with gemcitabine/Abraxane. Scale bar: 100 μm, n = 3 mice per group. c Representative mCerulean lifetime maps (top images) and longitudinal quantification of mCerulean lifetimes (lower left hand panels) and CDK1 activity (lower right hand panels) in fl-CCs injected with (i) fl-e-CAFs, with (ii) mt-e-CAFs WT or with (iii) mt-e-CAFs KO HSPG2 (mixed population) at 24 h, 48 h, and 72 h after treatment with control or with gemcitabine/Abraxane. Scale bar: 100 μm, n = 3 mice per group. The threshold was calculated based on values between untreated and treated mice at 24 h post-treatment with gemcitabine/Abraxane for each group of cells co-injected subcutaneously. See Supplementary information for details on calculation of threshold. Individual data points are presented with mean values and SEM. *p < 0.05